Therapeutic Uses
Anti-Cancer / Oncology
Storage Condition
Store at refrigerator (2-8°C) for long term storage
Synonyms
N-[5-[(4-Ethyl-1-piperazinyl-2,2,3,3,5,5,6,6-d8)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-2-pyrimidinamine
Application Notes
Useful research chemical for a range of applications
Purity by HPLC
Not less than 90%
Hazard Compound
No -Refer MSDS for accurate information
Abemaciclib-d8 is a drug product that is used as an analytical standard for HPLC, as well as in research and development of drugs.
Refund Policy
We are committed to offering products of the highest quality in order to meet the needs of our customers, and have elaborate systems in
place to ensure that material specifications, their certification and all handling and storage conditions are communicated at the time of
material handover.
We have invested in the highest quality packaging materials and use international logistics partners to service our customers. While all
possible precautions have been taken to deliver the required product(s), there may be some rare situations when our product does not
meet your requirements. Should that arise, please contact us with your concerns and we will endeavour to address them on a priority
basis. If there is no other option, we will either replace your product(s) or issue a refund or account credit, whichever you prefer.
If there is an issue with one or more of our products, our policy is that it must be reported to us within 45 days of your receiving shipment.
While we will always address product issues after the 45 day return window has passed, we cannot issue a refund or account credit. As
always, we appreciate your support.
Abemaciclib-d8 usage and description
Abemaciclib D8 is a deuterated form of the FDA-approved drug Abemaciclib. It is a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), which are enzymes involved in cell cycle progression and cell division. By inhibiting CDK4/6, Abemaciclib D8 can stop the growth and proliferation of cancer cells, particularly those found in breast cancer.
Abemaciclib D8 is typically administered orally in the form of tablets, and the recommended dosage depends on the patient's age, weight, and overall health status. It is usually taken twice daily, with or without food, and should be swallowed whole with a glass of water. Patients should not crush, chew, or break the tablets as doing so may affect the way the medication is absorbed by the body.
In terms of chemical information, Abemaciclib D8 has a molecular formula of C27H32D8N8O2, and a molecular weight of 484.7 g/mol. It is a white to off-white powder that is slightly soluble in water and ethanol. The deuterium labeling of Abemaciclib D8 does not affect its pharmacological activity or toxicity and is instead used as a tool in pharmacokinetic studies to track the drug's distribution, metabolism, and elimination in the body.
Like all medications, Abemaciclib D8 may cause side effects, such as diarrhea, nausea, fatigue, decreased appetite, and infections. Patients taking Abemaciclib D8 should also undergo regular blood tests to monitor their liver and kidney function and to check for any potential drug interactions with other medications they may be taking.
